NasdaqGS - Nasdaq Real Time Price ? USD Tourmaline Bio, Inc. (TRML) Follow Compare 23.01 +0.29 (+1.28%) At close: November 22 at 4:00 PM EST 22.06 -0.95 (-4.13%) After hours: 7:58 PM EST All News Press Releases SEC Filings All SEC Filings Corporate Changes & Voting Matters Periodic Financial Reports Proxy Statements Tender Offer/Acquisition Reports Offering Registrations Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024 NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, announced today that it will host a virtual Investor Day on December 10, 2024, beginning at 10 a.m. ET. The event will include presentations from Tourmaline's leadership team and Dr. Marc Bonaca, a cardiologist and vascular med GlobeNewswire ? 8 days ago TRML +1.28% Tourmaline Bio, Inc. Reports Third Quarter Financial Results Tourmaline Bio, Inc. ( (TRML) ) has released its Q3 earnings. Here is a breakdown of the information Tourmaline Bio, Inc. presented to its investors. Tourmaline Bio, Inc. is a clinical-stage biotechnology company focused on developing transformative treatments for immune and inflammatory diseases, primarily through its lead candidate pacibekitug, a monoclonal antibody targeting interleukin-6. In its latest earnings report, the company disclosed significant financial movements, with a noticeable TipRanks ? 9 days ago TRML +1.28% Tourmaline Bio Reports Third Quarter 2024 Financial Results and Recent Business Highlights – On track to report topline data from Phase 2 TRANQUILITY trial in first half of 2025 – – Assembled Cardiovascular Scientific Advisory Board (CV SAB), comprised of leading academic and industry experts, in October 2024 – – Showcased poster presentations at the American Society of Preventive Cardiology Annual Congress in August 2024 and the 19th Annual Cardiometabolic Health Congress in October 2024 – – Cash, cash equivalents and investments of $314.4 million as of September 30, 2024, providing GlobeNewswire ? 15 days ago TRML +1.28% Tourmaline Bio to Present at Upcoming Investor Conferences NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer, is expected to participate in the following investor conferences: Truist Securities BioPharma Symposium, New YorkPanel: Close to Heart: Innovati GlobeNewswire ? 22 days ago TRML +1.28% Tourmaline Bio to Host Expert Webinar on Human Genetic Validation for IL-6 Inhibition in Cardiovascular Disease with Dr. Dipender Gill on Friday, November 1, 2024 NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, announced today that it will host a webinar, Understanding the Genetic Validation for IL-6 Inhibition in Cardiovascular Disease, featuring Dr. Dipender Gill, CEO and Founder of Sequoia Genetics. The webinar will be held on Frid GlobeNewswire ? last month TRML +1.28% Tourmaline Bio to Showcase Two Poster Presentations at the 2024 Cardiometabolic Health Congress NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that it expects to present two posters at the upcoming 19th Annual Cardiometabolic Health Congress (CMHC), taking place October 17-19, 2024, in Boston, MA. These posters highlight Tourmaline's ongoing commitment GlobeNewswire ? last month TRML +1.28% Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board – Tourmaline assembles leading experts to support the development of pacibekitug for cardiovascular diseases – – Cardiovascular Scientific Advisory Board expected to provide strategic guidance as Tourmaline advances pacibekitug towards potential Phase 3 clinical trial readiness in 2025 for the treatment of cardiovascular diseases – NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative me GlobeNewswire ? last month TRML +1.28% Bullish Tourmaline Bio Insiders Loaded Up On US$643.3k Of Stock When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase... Simply Wall St. ? 3 months ago TRML +1.28% Tourmaline Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights – First patient dosed in May 2024 in Phase 2 TRANQUILITY trial evaluating pacibekitug (TOUR006) in patients with high cardiovascular risk – – On track to initiate a pivotal Phase 3 trial evaluating pacibekitug delivered subcutaneously every 8 weeks as first-line treatment for Thyroid Eye Disease (TED) in the second half of 2024 – – Added to the Russell 2000? Index and the broad-market Russell 3000? Index in June 2024 – – Cash, cash equivalents and investments of $334.4 million as of June 30, 202 GlobeNewswire ? 3 months ago TRML +1.28% Tourmaline Bio Presents Phase 2 TRANQUILITY Study Design at American Society of Preventive Cardiology (ASPC) Congress 2024 Phase 2 TRANQUILITY trial is evaluating the high-sensitivity C-reactive protein (hs-CRP)-lowering effect, safety, tolerability, and pharmacokinetics (PK) of quarterly and monthly subcutaneous administration of TOUR006 in patients with chronic kidney disease and elevated hs-CRP — Dosing regimens are informed by six previous Phase 1 and Phase 2 clinical studies in healthy volunteers and patients with inflammatory autoimmune disorders, as well as PK/PD modeling —Topline data is expected first half GlobeNewswire ? 3 months ago TRML +1.28% Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced the promotion of Ryan Robinson, CPA, to Chief Financial Officer and Treasurer, effective June 25, 2024. Mr. Robinson most recently held the role of Vice President, Finance and Controller at Tourmaline, in additi GlobeNewswire ? 4 months ago TRML +1.28% Tourmaline Bio to Present at the Jefferies Global Healthcare Conference NEW YORK, May 23, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, CEO, is expected to participate in the following investor conference: Jefferies Global Healthcare Conference, New YorkCorporate PresentationThursday, June 6, 2024 at 2:30 pm ET A live webca GlobeNewswire ? 5 months ago TRML +1.28% Tourmaline Bio Initiates Clinical Development of TOUR006 for Cardiovascular Diseases with First Patient Dosed in Phase 2 TRANQUILITY Trial – First patient dosed in trial to evaluate the safety, pharmacokinetics and pharmacodynamics of TOUR006 in patients with inflammatory risk and chronic kidney disease – – Topline data anticipated in the first half of 2025 with potential to advance TOUR006 toward Phase 3 readiness for atherosclerotic cardiovascular disease (ASCVD) and other cardiovascular diseases – – TRANQUILITY trial intended to provide evidence of TOUR006’s best-in-class potential for ASCVD, including the potential for quarterl GlobeNewswire ? 6 months ago TRML +1.28% Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights – Initiated Phase 2 TRANQUILITY trial in April 2024 following U.S. FDA clearance of Investigational New Drug application (IND) for clinical development program in Atherosclerotic Cardiovascular Disease (ASCVD) – – Expanded Thyroid Eye Disease (TED) clinical development plan, including accelerating the planned initiation of a pivotal Phase 3 trial into 2024 – – Completed underwritten follow-on public offering in January 2024, raising gross proceeds of $172.5 million – – Ended the quarter with $35 GlobeNewswire ? 6 months ago TRML +1.28% Avalo Therapeutics Appoints Biotech Leaders to Board of Directors Appointments include industry veterans Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent DirectorsBoard of Director appointments in conjunction with Avalo’s recent acquisition of AVTX-009, an anti-IL-1β mAb, and up to $185 million private placement financing WAYNE, Pa. and ROCKVILLE, Md., April 02, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) today announced the addition of multiple biotech leaders to its Board of Directors. The Avalo Board brings together a GlobeNewswire ? 7 months ago AVTX TRML +1.28% Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights – Initiated pivotal spiriTED Phase 2b trial in Thyroid Eye Disease (TED) in 2023 and expanded TED clinical development plan, including accelerating the planned initiation of a pivotal Phase 3 trial into 2024 – – Reached alignment with the U.S. FDA on the clinical development program in Atherosclerotic Cardiovascular Disease (ASCVD) in 2023 and received clearance for Investigational New Drug application (IND) in March 2024 – – Completed reverse merger with Talaris Therapeutics in October 2023, in GlobeNewswire ? 8 months ago TRML +1.28% Tourmaline Bio to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference NEW YORK, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, CEO, will present at the in the following investor conference: Guggenheim Healthcare Talks | 6th Annual Biotechnology ConferenceFireside chat February 7, 2024 at 11:00am ET A live webcast GlobeNewswire ? 9 months ago TRML +1.28% Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares NEW YORK, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced the closing of its previously-announced underwritten public offering of 5,307,691 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 692,307 additional shares, GlobeNewswire ? 9 months ago TRML +1.28% Tourmaline Bio Announces Pricing of Public Offering of Common Stock NEW YORK, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced the pricing of an underwritten public offering of 4,615,384 shares of its common stock, at a public offering price of $32.50 per share. The gross proceeds to Tourmaline from the offering, before deducting unde GlobeNewswire ? 9 months ago TRML +1.28% Tourmaline Bio Announces Proposed Public Offering of Common Stock NEW YORK, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced the launch of a proposed underwritten public offering of its common stock. All shares of common stock to be sold in the proposed offering will be sold by Tourmaline. In addition, Tourmaline expects to grant th GlobeNewswire ? 9 months ago TRML +1.28% Performance Overview Trailing total returns as of 11/22/2024, which may include dividends or other distributions. Benchmark is S&P 500 Return TRML S&P 500 YTD -12.11% +25.15% 1-Year +30.81% +31.54% 3-Year -60.43% +27.06%
